Zobrazeno 1 - 10
of 186
pro vyhledávání: '"R. Morlock"'
Publikováno v:
European Urology Open Science, Vol 19, Iss , Pp e867-e868 (2020)
Externí odkaz:
https://doaj.org/article/a314ec88ebb442cfb8b1d07e2ffb1dd5
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Frontiers in Psychiatry, Vol 12 (2022)
Frontiers in Psychiatry
Frontiers in Psychiatry
Introduction: Popular media coverage of psychedelics use, growing research into this class of compounds for psychiatry and decriminalization initiatives, are transforming the public perception of psychedelics. However, little is known about levels of
Autor:
Maya Leventer-Roberts, Dana Y. Teltsch, Arriel Benis, Hagit Gabay, R. Morlock, Natalia M. Flores, Jonathan Chapnick, Shmuel Giveon, Dena H Jaffe, Becca Feldman, Yair Molad, Alyssa B Klein
Publikováno v:
BMC Rheumatology, Vol 3, Iss 1, Pp 1-11 (2019)
BMC Rheumatology
BMC Rheumatology
Background Uncontrolled gout can cause significant joint and organ damage and has been associated with impairments in quality of life and high economic cost. Gout has also been associated with other comorbid diseases, such as chronic kidney disease.
Publikováno v:
Fertility and Sterility. 116:e404-e405
Publikováno v:
Annals of the Rheumatic Diseases. 81:1648.1-1648
BackgroundBy definition, uncontrolled gout (UG) cannot be managed with oral urate lowering therapies (ULTs) and is associated with substantial morbidity. UG, also known as refractory gout, results in escalated treatment and management. Recent America
Publikováno v:
Gastric Cancer
Background Zolbetuximab plus first-line EOX (epirubicin, oxaliplatin, capecitabine; ZOL/EOX) significantly prolonged progression-free survival and overall survival in the FAST trial vs EOX alone. We report the patient-reported outcomes (PROs) of FAST
Autor:
R. Morlock, J Geraci
Publikováno v:
Value in Health. 25:S275
Publikováno v:
Journal of Medical Economics. 22:1-6
Aim: To evaluate the burden of uncontrolled gout by examining estimated costs and cost drivers. Materials and methods: Data from the 2012 and 2013 US National Health and Wellness Survey (NHWS; 2012 NHWS, n = 71,157 and 2013 NHWS, n = 75,000) were uti